EIF4EBP1 and hepatocellular carcinoma: For HCV HCC, 5 from 10 expressed p-mTOR and 6 from 10 were p-4E-BP1 positive, and for the NASH HCC group, 9 from 10 expressed p-mTOR and 8 from 10 were p-4E-BP1 positive (Fig 6C).